Generic Name and Formulations:
Clevidipine butyrate emulsion 0.5mg/mL; soln for IV infusion; contains lipids 0.2g/mL (soybean oil, egg phospholipids).
Chiesi USA, Inc.
Indications for CLEVIPREX:
To reduce blood pressure when oral therapy is not feasible or desirable.
≥18yrs: Individualize; titrate. Give by IV infusion. Initially 1–2mg/hr; double dose at 90sec intervals until BP approaches goal, then titrate slower (adjust at 5–10min intervals). Dose increases of 1–2mg/hr results in systolic BP lowering of about 2–4mmHg. Maintenance: 4–6mg/hr; usual max 16–32mg/hr. Do not exceed 1000mL (21mg/hr for 24hrs) due to lipid load. Switch to oral therapy when indicated.
<18yrs: not recommended.
Egg or soy allergy. Defective lipid metabolism (eg, pathologic hyperlipemia, lipoid nephrosis, acute pancreatitis with hyperlipidemia). Severe aortic stenosis.
Maintain aseptic technique. Monitor BP and pulse during infusion and until stabilized. Heart failure (monitor). Monitor for rebound hypertension for at least 8hrs after stopping infusion (if not given other antihypertensives after prolonged infusion). Avoid abrupt cessation of any β-blocker treatment. Pheochromocytoma. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Calcium channel blocker (CCB) (dihydropyridine).
Headache, nausea, vomiting; hypotension, reflex tachycardia (slow infusion if occurs, do not use beta-blocker); rare: myocardial infarction, cardiac arrest, syncope, dyspnea.
Single-use vials—50mL, 100mL
Neurology Advisor Articles
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Gender Differences in the Epidemiology of Migraine
- Changes in Glucose Regulation in Parkinson Disease
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Locally Asymptomatic Ischemic Stroke May Present as Migraine Aura
- Associations Identified Between Stroke Severity, Recovery of Visuospatial Neglect
- Action Tremor May Have Central Origin in Motor Neuron Disease
- Characteristics Affecting Health-Related Quality of Life in RRMS, Progressive MS
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd